A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Jul 2017 Planned primary completion date changed from 28 Jun 2018 to 5 May 2021.
- 23 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jul 2021.
- 13 Jul 2015 Planned number of patients changed from 225 to 245, as per ClinicalTrials.gov record.